1. Neurochemical changes in the progression of Huntington's disease: A meta-analysis of in vivo 1 H-MRS studies.
- Author
-
Jing Y, Dogan I, Reetz K, and Romanzetti S
- Subjects
- Humans, Creatine metabolism, Inositol metabolism, Aspartic Acid analogs & derivatives, Aspartic Acid metabolism, Brain metabolism, Brain diagnostic imaging, Huntington Disease metabolism, Huntington Disease genetics, Disease Progression, Proton Magnetic Resonance Spectroscopy methods
- Abstract
Proton magnetic resonance spectroscopy (
1 H-MRS) allows measuring specific brain metabolic alterations in Huntington's disease (HD), and these metabolite profiles may serve as non-invasive biomarkers associated with disease progression. Despite this potential, previous findings are inconsistent. Accordingly, we performed a meta-analysis on available in vivo1 H-MRS studies in premanifest (Pre-HD) and symptomatic HD stages (Symp-HD), and quantified neurometabolic changes relative to controls in 9 Pre-HD studies (227 controls and 188 mutation carriers) and 14 Symp-HD studies (326 controls and 306 patients). Our results indicated decreased N-acetylaspartate and creatine in the basal ganglia in both Pre-HD and Symp-HD. The overall level of myo-inositol was decreased in Pre-HD while increased in Symp-HD. Besides, Symp-HD patients showed more severe metabolism disruption than Pre-HD patients. Taken together,1 H-MRS is important for elucidating progressive metabolite changes from Pre-HD to clinical conversion; N-acetylaspartate and creatine in the basal ganglia are already sensitive at the preclinical stage and are promising biomarkers for tracking disease progression; overall myo-inositol is a possible characteristic metabolite for distinguishing HD stages., Competing Interests: Declaration of competing interest The authors report no conflict of interest., (Copyright © 2023. Published by Elsevier Inc.)- Published
- 2024
- Full Text
- View/download PDF